LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Expanding indications for permanent pacemakers.

    Glikson, M / Espinosa, R E / Hayes, D L

    Annals of internal medicine

    1995  Volume 123, Issue 6, Page(s) 443–451

    Abstract: ... published from 1980 through 1994 about indications for permanent pacing. Five major areas were identified ... Purpose: To review the current clinical experience with new and expanding indications ... the promising effects of pacing in patients with these newly recognized and expanding indications for pacing. ...

    Abstract Purpose: To review the current clinical experience with new and expanding indications for permanent cardiac pacing.
    Data sources: A MEDLINE search was done of the English-language literature published from 1980 through 1994 about indications for permanent pacing. Five major areas were identified and searched: cardiomyopathies, atrial fibrillation, the long QT syndrome, cardiac transplantation, and vasovagal syncope. A manual search was then done for other contributions, including abstracts.
    Study selection: Because published reports in these areas are scarce, all of the peer-reviewed articles and most of the relevant abstracts found were reviewed.
    Data extraction: Data were manually extracted from the various sources, and the reports were classified and summarized according to specific indications.
    Results: Pacing is becoming an important option in the treatment of patients with symptomatic drug-resistant hypertrophic obstructive cardiomyopathy. Symptomatic and hemodynamic benefits have been shown in patients with pacing over various periods of follow-up. In patients with the long QT syndrome in whom medical therapy had failed, pacing at relatively fast rates markedly reduced symptoms and almost completely abolished fainting spells. Preliminary results suggest that pacing may be beneficial in dilated cardiomyopathy and in preventing episodes of paroxysmal atrial fibrillation. Further studies are needed to clarify the mechanisms of and to improve selection criteria for pacing in these conditions. Our ability to select cardiac transplant recipients for permanent pacing and our ability to optimize the timing of pacing in these patients have recently improved considerably. The role of pacing therapy in patients with neurally mediated (vasovagal) syncope remains incompletely understood. Better classification of these patients, made according to the sequence of hemodynamic events leading to syncope, is likely to clarify the potential benefit of pacing in these patients and improve the selection of patients for pacing.
    Conclusion: Few peer-reviewed clinical trials have been done, and further studies are needed to confirm the promising effects of pacing in patients with these newly recognized and expanding indications for pacing.
    MeSH term(s) Atrial Fibrillation/prevention & control ; Cardiac Pacing, Artificial ; Cardiomyopathies/physiopathology ; Cardiomyopathies/therapy ; Heart Transplantation ; Hemodynamics ; Humans ; Long QT Syndrome/therapy ; Syncope/therapy
    Language English
    Publishing date 1995-09-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/0003-4819-123-6-199509150-00009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Expanding indications for resynchronization therapy.

    Leclercq, Christophe / Behar, Nathalie / Mabo, Philippe / Daubert, Jean-Claude

    Current cardiology reports

    2012  Volume 14, Issue 5, Page(s) 540–546

    Abstract: ... might benefit from CRT. This is the case for patients with permanent atrial fibrillation, patients conventional ... pacemaker indication, patients with mildly impaired left ventricular function (>35 %), or asymptomatic ...

    Abstract Cardiac resynchronization therapy (CRT) is one of the major advances in the treatment of patients with chronic heart failure due to impaired left ventricular ejection fraction. Current guidelines recommend with the highest levels of recommendation and evidence CRT in patients with low ejection fraction wide QRS, LBBB, and mild to severe heart failure (New York Heart Association class II to IV). However, other patients might benefit from CRT. This is the case for patients with permanent atrial fibrillation, patients conventional pacemaker indication, patients with mildly impaired left ventricular function (>35 %), or asymptomatic patients (NYHA I). We will discuss in this manuscript each new potential indication for CRT.
    MeSH term(s) Atrial Fibrillation/therapy ; Bradycardia/therapy ; Cardiac Pacing, Artificial/methods ; Cardiac Resynchronization Therapy/methods ; Cardiac Resynchronization Therapy Devices ; Defibrillators, Implantable ; Disease Progression ; Electrocardiography ; Heart Failure/therapy ; Humans ; Pacemaker, Artificial ; Stroke Volume ; Treatment Outcome ; Ventricular Dysfunction, Left/therapy ; Ventricular Remodeling
    Language English
    Publishing date 2012-07-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2055373-0
    ISSN 1534-3170 ; 1523-3782
    ISSN (online) 1534-3170
    ISSN 1523-3782
    DOI 10.1007/s11886-012-0299-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Balloon-expandable versus self-expanding transcatheter aortic valve replacement: a comparison and evaluation of current findings.

    Costa, Giuliano / Criscione, Enrico / Reddavid, Claudia / Barbanti, Marco

    Expert review of cardiovascular therapy

    2020  Volume 18, Issue 10, Page(s) 697–708

    Abstract: ... PVR) and permanent pacemaker implantation (PPI), whereas SE TAVs had better performance in terms ... the expansion of TAVR indications toward lower risk, younger patients imposes attention to long-term durability ... Introduction: Currently, several balloon-expandable (BE) and self-expanding (SE) transcatheter ...

    Abstract Introduction: Currently, several balloon-expandable (BE) and self-expanding (SE) transcatheter aortic valves (TAVs) are available in clinical practice. Each of them has potential advantages and disadvantages that must be taken into account.
    Areas covered: New-generation BE and SE TAVs showed similar mid-term outcomes after transfemoral transcatheter aortic valve replacement (TAVR) and better results compared to early-generation devices.BE TAVs showed better results in terms of residual paravalvular regurgitation (PVR) and permanent pacemaker implantation (PPI), whereas SE TAVs had better performance in terms of residual transvalvular gradients, larger effective orifice areas (EOAs) and therefore lower rates of prosthesis-patients mismatch (PPM). On one hand, supra-annular CoreValve/Evolut SE TAVs seems to have better results compared to SAPIEN XT/3 BE valves when used in the setting of valve-in-valve procedures in small bioprostheses. On the other hand, the need of ensuring an easy coronary re-access after TAVR especially in younger patients seems to favor the large cell design of SAPIEN 3/ULTRA BE valves. Finally, first long-term durability reports seem to suggest lower rates of structural valve dysfunction (SVD) with supra-annular SE TAVs.
    Expert opinion: Although currently available TAVs showed similar mid-term outcomes, the expansion of TAVR indications toward lower risk, younger patients imposes attention to long-term durability, and to the need of obtaining optimized EOAs and an easy coronary re-access for future percutaneous interventions.
    MeSH term(s) Aortic Valve/surgery ; Aortic Valve Stenosis/surgery ; Bioprosthesis ; Heart Valve Prosthesis ; Humans ; Prosthesis Design ; Risk ; Transcatheter Aortic Valve Replacement ; Treatment Outcome
    Language English
    Publishing date 2020-08-13
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 2192343-7
    ISSN 1744-8344 ; 1477-9072
    ISSN (online) 1744-8344
    ISSN 1477-9072
    DOI 10.1080/14779072.2020.1807326
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Initial Experience of a Second-Generation Self-Expanding Transcatheter Aortic Valve: The UK & Ireland Evolut R Implanters' Registry.

    Kalra, Sundeep S / Firoozi, Sami / Yeh, James / Blackman, Daniel J / Rashid, Shabnam / Davies, Simon / Moat, Neil / Dalby, Miles / Kabir, Tito / Khogali, Saib S / Anderson, Richard A / Groves, Peter H / Mylotte, Darren / Hildick-Smith, David / Rampat, Rajiv / Kovac, Jan / Gunarathne, Ashan / Laborde, Jean-Claude / Brecker, Stephen J

    JACC. Cardiovascular interventions

    2017  Volume 10, Issue 3, Page(s) 276–282

    Abstract: ... major vascular in 5.3%, acute kidney injury in 6.1%, new permanent pacemaker implantation in 14.7%, and ... Risk Evaluation score was 19.9 ± 13.7%. Procedural indications included aortic stenosis (72.0%), mixed ... of the Evolut R transcatheter heart valve.: Background: The Evolut R is a self-expanding, repositionable, and ...

    Abstract Objectives: The authors present the UK and Irish real-world learning curve experience of the Evolut R transcatheter heart valve.
    Background: The Evolut R is a self-expanding, repositionable, and fully recapturable second-generation transcatheter heart valve with several novel design features to improve outcomes and reduce complications.
    Methods: Clinical, procedural, and 30-day outcome data were prospectively collected for the first 264 patients to receive the Evolut R valve in the United Kingdom and Ireland.
    Results: A total of 264 consecutive Evolut R implantations were performed across 9 centers. The mean age was 81.1 ± 7.8 years, and the mean logistic European System for Cardiac Operative Risk Evaluation score was 19.9 ± 13.7%. Procedural indications included aortic stenosis (72.0%), mixed aortic valve disease (17.4%), and failing aortic valve bioprostheses (10.6%). Conscious sedation was used in 39.8% of patients and transfemoral access in 93.6%. The procedural success rate was 91.3%, and paravalvular leak immediately after implantation was mild or less in 92.3%. Major complications were rare: cardiac tamponade in 0.4%, conversion to sternotomy in 0.8%, annular rupture in 0.0%, coronary occlusion in 0.8%, major vascular in 5.3%, acute kidney injury in 6.1%, new permanent pacemaker implantation in 14.7%, and procedure-related death in 0.0%. At 30-day follow-up, survival was 97.7%, paravalvular leak was mild or less in 92.3%, and the stroke rate was 3.8%.
    Conclusions: This registry represents the largest published real-world experience of the Evolut R valve. The procedural success rate was high and safety was excellent, comparable with previous studies of the Evolut R valve and other second-generation devices. The low rate of complications represents an improvement on first-generation devices.
    MeSH term(s) Aged ; Aged, 80 and over ; Aortic Valve/diagnostic imaging ; Aortic Valve/physiopathology ; Aortic Valve/surgery ; Aortic Valve Insufficiency/diagnostic imaging ; Aortic Valve Insufficiency/mortality ; Aortic Valve Insufficiency/physiopathology ; Aortic Valve Insufficiency/surgery ; Aortic Valve Stenosis/diagnostic imaging ; Aortic Valve Stenosis/mortality ; Aortic Valve Stenosis/physiopathology ; Aortic Valve Stenosis/surgery ; Clinical Competence ; Female ; Heart Valve Prosthesis ; Humans ; Ireland ; Learning Curve ; Male ; Postoperative Complications/etiology ; Prospective Studies ; Prosthesis Design ; Registries ; Risk Assessment ; Risk Factors ; Time Factors ; Transcatheter Aortic Valve Replacement/adverse effects ; Transcatheter Aortic Valve Replacement/instrumentation ; Transcatheter Aortic Valve Replacement/mortality ; Treatment Outcome ; United Kingdom
    Language English
    Publishing date 2017-02-09
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2452157-7
    ISSN 1876-7605 ; 1936-8798
    ISSN (online) 1876-7605
    ISSN 1936-8798
    DOI 10.1016/j.jcin.2016.11.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top